Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 98 articles: HTML format

Single Articles

July 2025
1. ROLFO C, O'Brate A, Menzel C, Bruns R, et al
   Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
   Clin Cancer Res. 2025;31:2675-2684.
   PubMed     Abstract available
   
   
   
2. JANG HJ, Patel M, Wang DY, Kang SW, et al
   Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.
   Clin Cancer Res. 2025;31:2639-2654.
   PubMed     Abstract available
   
   
   June 2025
3. GAY CM, Owonikoko TK, Byers LA, Choudhury NJ, et al
   Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell Lung Cancer Molecular Subtypes.
   Clin Cancer Res. 2025 Jun 24. doi: 10.1158/1078-0432.CCR-24-3981.
   PubMed     Abstract available
   
   
   
4. DAVAR D, Eroglu Z, Milhem M, Becerra C, et al
   Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
   Clin Cancer Res. 2025 Jun 24:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0806.
   PubMed     Abstract available
   
   
   
5. DAVIES KD
   Finding Rearrangements in the Cell-Free DNA Haystack.
   Clin Cancer Res. 2025;31:2264-2266.
   PubMed     Abstract available
   
   
   
6. PAWELETZ CP, Urvalek A, Ha M, Garg K, et al
   Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
   Clin Cancer Res. 2025;31:2406-2412.
   PubMed     Abstract available
   
   
   
7. MACK PC, Redman MW, Tukachinsky H, Kozono DE, et al
   Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
   Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658.
   PubMed     Abstract available
   
   
   
8. ANDREWS HS, Zariffa N, Nishimura KK, Choi SH, et al
   ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.
   Clin Cancer Res. 2025;31:2162-2172.
   PubMed     Abstract available
   
   
   May 2025
9. CHENG Y, Wang J, Yu Y, Wang Q, et al
   Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
   Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022.
   PubMed     Abstract available
   
   
   April 2025
10. ZHANG J, Jin Y, Lin H, Deng J, et al
    Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3399.
    PubMed     Abstract available
    
    
    
11. HIRSCH FR
    Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?
    Clin Cancer Res. 2025 Apr 28. doi: 10.1158/1078-0432.CCR-25-0839.
    PubMed     Abstract available
    
    
    
12. ZHOU J, Muluneh B, Wang Z, Yao H, et al
    Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 24. doi: 10.1158/1078-0432.CCR-25-0292.
    PubMed     Abstract available
    
    
    
13. PECCI F, Thummalapalli R, Alden SL, Ricciuti B, et al
    Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 18:OF1-OF13. doi: 10.1158/1078-0432.CCR-24-2990.
    PubMed     Abstract available
    
    
    
14. JENG MY, Schoenfeld AJ
    Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
    Clin Cancer Res. 2025;31:1381-1382.
    PubMed     Abstract available
    
    
    
15. MAZZASCHI G, Marrocchio C, Moron Dalla Tor L, Leo L, et al
    Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
    Clin Cancer Res. 2025;31:1533-1545.
    PubMed     Abstract available
    
    
    March 2025
16. KANDA S, Niho S, Kurata T, Nomura S, et al
    Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Clin Cancer Res. 2025 Mar 31. doi: 10.1158/1078-0432.CCR-24-3532.
    PubMed     Abstract available
    
    
    
17. KATAYAMA Y, Yamada T, Tanimura K, Kawachi H, et al
    YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
    Clin Cancer Res. 2025;31:1127-1141.
    PubMed     Abstract available
    
    
    
18. TRONTZAS IP, He M, Wurtz A, Robbins CJ, et al
    Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347.
    PubMed     Abstract available
    
    
    February 2025
19. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Clin Cancer Res. 2025;31:788.
    PubMed    
    
    
    
20. WOJTALLA A, Fischer B, Kotelevets N, Mauri FA, et al
    Correction: Targeting the Phosphoinositide 3-Kinase p110-alpha Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.
    Clin Cancer Res. 2025;31:787.
    PubMed    
    
    
    
21. AGGARWAL RK, Sidoli S, Wang J, Sahu S, et al
    Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation.
    Clin Cancer Res. 2025;31:746-755.
    PubMed     Abstract available
    
    
    
22. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    PubMed     Abstract available
    
    
    
23. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    PubMed     Abstract available
    
    
    January 2025
24. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed     Abstract available
    
    
    
25. ZHANG JT, Liu SY, Gao X, Liu SM, et al
    Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Jan 24. doi: 10.1158/1078-0432.CCR-24-2909.
    PubMed     Abstract available
    
    
    
26. KATO R, Solanki HS, Ozakinci H, Desai B, et al
    In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C--mutant non-small cell lung cancer.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3714.
    PubMed     Abstract available
    
    
    
27. CAPPUZZO F, Ricciuti B, Delmonte A, Bonanno L, et al
    MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-2077.
    PubMed     Abstract available
    
    
    
28. SMEENK MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al
    Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer: the Induction trial.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3476.
    PubMed     Abstract available
    
    
    
29. ROSNER S, Connor S, Sanber K, Zahurak M, et al
    Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
    Clin Cancer Res. 2025;31:339-351.
    PubMed     Abstract available
    
    
    
30. REINECKE JB, Jimenez Garcia L, Gross AC, Cam M, et al
    Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells.
    Clin Cancer Res. 2025;31:414-429.
    PubMed     Abstract available
    
    
    
31. DALL'OLIO FG, Zrafi W, Roelants V, Ambrosini V, et al
    Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
    Clin Cancer Res. 2025;31:352-364.
    PubMed     Abstract available
    
    
    
32. NEGRAO MV, Paula AG, Molkentine D, Hover L, et al
    Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.
    Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-2310.
    PubMed     Abstract available
    
    
    
33. MEADOR CB, Digumarthy SR, Yeap BY, Hung YP, et al
    Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.
    Clin Cancer Res. 2025;31:25-34.
    PubMed     Abstract available
    
    
    
34. SCHULER M
    Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-1441.
    PubMed     Abstract available
    
    
    December 2024
35. LEE S, Hamid O, Jotte R, Zakharia Y, et al
    Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478.
    PubMed     Abstract available
    
    
    
36. AOKAGE K, Koyama S, Kumagai S, Nomura K, et al
    Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
    Clin Cancer Res. 2024;30:5584-5592.
    PubMed     Abstract available
    
    
    
37. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    PubMed     Abstract available
    
    
    
38. VON ITZSTEIN MS, Burns TF, Dowell JE, Horn L, et al
    Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
    Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722.
    PubMed     Abstract available
    
    
    November 2024
39. ALTAN M, Lopes G, Hiltermann TJN, Govindan R, et al
    Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591.
    PubMed     Abstract available
    
    
    
40. SOO RA, Dafni U, Han JY, Cho BC, et al
    ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
    Clin Cancer Res. 2024;30:5180-5191.
    PubMed     Abstract available
    
    
    October 2024
41. STEWART CA, Diao L, Xi Y, Wang R, et al
    YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
    Clin Cancer Res. 2024;30:4743-4754.
    PubMed     Abstract available
    
    
    
42. VERKERK K, van der Wel TJWT, Zeverijn LJ, Geurts BS, et al
    Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol.
    Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1925.
    PubMed     Abstract available
    
    
    
43. LIZARDO MM, Hughes C, Huang YZ, Shyp T, et al
    Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.
    Clin Cancer Res. 2024;30:4464-4481.
    PubMed     Abstract available
    
    
    September 2024
44. MORGENSZTERN D, Ready N, Johnson ML, Dowlati A, et al
    A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Sep 17. doi: 10.1158/1078-0432.CCR-24-1547.
    PubMed     Abstract available
    
    
    
45. VOKES NI, Le X, Yap TA
    PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
    Clin Cancer Res. 2024;30:3968-3970.
    PubMed     Abstract available
    
    
    
46. CHOI Y, Dharia NV, Jun T, Chang J, et al
    Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
    Clin Cancer Res. 2024;30:3788-3797.
    PubMed     Abstract available
    
    
    
47. EL ZARIF T, Meador CB, Qiu X, Seo JH, et al
    Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
    Clin Cancer Res. 2024;30:3798-3811.
    PubMed     Abstract available
    
    
    August 2024
48. KOBAN MU, Hartmann M, Amexis G, Franco P, et al
    Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-0741.
    PubMed     Abstract available
    
    
    
49. OH S, Koh J, Kim TM, Kim S, et al
    Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer.
    Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-0160.
    PubMed     Abstract available
    
    
    July 2024
50. REINMUTH N, Juan-Vidal O, Kowalski D, Bryl M, et al
    Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013.
    PubMed     Abstract available
    
    
    
51. SUVILESH KN, Manjunath Y, Nussbaum YI, Gadelkarim M, et al
    Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-23-3980.
    PubMed     Abstract available
    
    
    
52. SCALERA S, Ricciuti B, Marinelli D, Mazzotta M, et al
    Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy.
    Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0626.
    PubMed     Abstract available
    
    
    
53. YANG SR, Jayakumaran G, Benhamida J, Febres-Aldana CA, et al
    Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.
    Clin Cancer Res. 2024;30:2780-2789.
    PubMed     Abstract available
    
    
    June 2024
54. CHOUDHURY NJ, Lai WV, Makhnin A, Heller G, et al
    A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer.
    Clin Cancer Res. 2024 Jun 28. doi: 10.1158/1078-0432.CCR-23-3383.
    PubMed     Abstract available
    
    
    
55. BARBATO MI, Bradford D, Ren Y, Aungst SL, et al
    FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
    Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949.
    PubMed     Abstract available
    
    
    
56. PANG L, Huang Y, Zhuang W, Zhang Y, et al
    Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
    Clin Cancer Res. 2024;30:2636-2646.
    PubMed     Abstract available
    
    
    
57. DALAL B, Tada T, Patel DP, Pine SR, et al
    Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Non-smokers and Tobacco Smokers.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0637.
    PubMed     Abstract available
    
    
    
58. ROLFO CD, Madison RW, Pasquina LW, Brown DW, et al
    Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.
    Clin Cancer Res. 2024;30:2452-2460.
    PubMed     Abstract available
    
    
    May 2024
59. FUKUDA A, Okuma Y
    From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035.
    PubMed     Abstract available
    
    
    
60. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    PubMed     Abstract available
    
    
    
61. REKHTMAN N
    All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
    Clin Cancer Res. 2024;30:1708-1711.
    PubMed     Abstract available
    
    
    
62. MARINIELLO A, Nasti TH, Chang DY, Hashimoto M, et al
    Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
    Clin Cancer Res. 2024;30:1833-1845.
    PubMed     Abstract available
    
    
    April 2024
63. ZHOU R, Liu F, Zhang H, Wang D, et al
    Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600.
    PubMed     Abstract available
    
    
    
64. ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al
    Facts and hopes on cancer immunotherapy for small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159.
    PubMed     Abstract available
    
    
    
65. PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al
    Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104.
    PubMed     Abstract available
    
    
    
66. GRAZINI U, Markovets A, Ireland L, O'Neill D, et al
    Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540.
    PubMed     Abstract available
    
    
    
67. OH HJ, Bae SC, Oh IJ, Park CK, et al
    Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Clin Cancer Res. 2024;30:1478-1487.
    PubMed     Abstract available
    
    
    
68. LEE EJ, Oh SY, Lee YW, Kim JY, et al
    Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Clin Cancer Res. 2024;30:1582-1594.
    PubMed     Abstract available
    
    
    
69. SINGH AK, Lewis CD, Boas CAWV, Diebolder P, et al
    Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.
    Clin Cancer Res. 2024;30:1293-1306.
    PubMed     Abstract available
    
    
    
70. VAIDYA P, Cohen EEW
    Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
    Clin Cancer Res. 2024;30:1232-1239.
    PubMed     Abstract available
    
    
    February 2024
71. ZHOU I, Plana D, Palmer AC
    Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Clin Cancer Res. 2024;30:786-792.
    PubMed     Abstract available
    
    
    
72. KASI PM, Lee JK, Pasquina LW, Decker B, et al
    Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
    Clin Cancer Res. 2024;30:836-848.
    PubMed     Abstract available
    
    
    
73. WEI D, Wang L, Zuo X, Maitra A, et al
    A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
    Clin Cancer Res. 2024;30:655-662.
    PubMed     Abstract available
    
    
    
74. WANG H, Chen Y, Wang X, Huang B, et al
    Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
    Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
    PubMed     Abstract available
    
    
    
75. VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al
    Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027.
    PubMed     Abstract available
    
    
    
76. LAKHANI NJ, Rasco D, Wang H, Men L, et al
    First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
    Clin Cancer Res. 2024;30:506-521.
    PubMed     Abstract available
    
    
    January 2024
77. PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al
    Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
    Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251.
    PubMed     Abstract available
    
    
    
78. GUAN S, Chen X, Wei Y, Wang F, et al
    Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients.
    Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357.
    PubMed     Abstract available
    
    
    
79. KESARI S, Wagle N, Carrillo JA, Sharma A, et al
    Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
    Clin Cancer Res. 2024;30:323-333.
    PubMed     Abstract available
    
    
    
80. NG J, Cai L, Girard L, Prall OWJ, et al
    Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360.
    PubMed     Abstract available
    
    
    
81. NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al
    Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
    PubMed     Abstract available
    
    
    December 2023
82. LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al
    Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
    Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457.
    PubMed     Abstract available
    
    
    
83. PASSIGLIA F, Righi L, Bironzo P, Listi A, et al
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.
    Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431.
    PubMed     Abstract available
    
    
    
84. BOUMELHA J, Molina-Arcas M, Downward J
    Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
    Clin Cancer Res. 2023;29:5012-5020.
    PubMed     Abstract available
    
    
    
85. HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al
    A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061.
    PubMed     Abstract available
    
    
    
86. ROLFO C, Russo A
    In search of lost biomarker for immunotherapy in small-cell lung cancer.
    Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087.
    PubMed     Abstract available
    
    
    
87. BESSEDE A, Peyraud F, Besse B, Cousin S, et al
    TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566.
    PubMed     Abstract available
    
    
    
88. VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al
    ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Clin Cancer Res. 2023;29:4958-4972.
    PubMed     Abstract available
    
    
    November 2023
89. MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al
    Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469.
    PubMed     Abstract available
    
    
    October 2023
90. HERBST RS, Blanke CD, Sigal EV
    Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
    Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
    PubMed     Abstract available
    
    
    
91. PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al
    Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689.
    PubMed     Abstract available
    
    
    September 2023
92. BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al
    Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928.
    PubMed     Abstract available
    
    
    
93. DIMOU A
    Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152.
    PubMed     Abstract available
    
    
    
94. SOLTA A, Boettiger K, Kovacs I, Lang C, et al
    Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795.
    PubMed     Abstract available
    
    
    
95. CANTOR DJ, Aggarwal C
    Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
    Clin Cancer Res. 2023;29:3563-3565.
    PubMed     Abstract available
    
    
    
96. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    PubMed     Abstract available
    
    
    
97. ABEL ML, Takahashi N, Peer C, Redon CE, et al
    Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:3603-3611.
    PubMed     Abstract available
    
    
    
98. PELLINI B, Madison RW, Childress M, Miller ST, et al
    Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.